235 related articles for article (PubMed ID: 29423648)
1. An integrated structure- and pharmacophore-based MMP-12 virtual screening.
Ramezani M; Shamsara J
Mol Divers; 2018 May; 22(2):383-395. PubMed ID: 29423648
[TBL] [Abstract][Full Text] [Related]
2. Virtual Screening on MMP-13 Led to Discovering New Inhibitors Including a Non-Zinc Binding and a Micro Molar One: A Successful Example of Receptor Selection According to Cross-Docking Results for a Flexible Enzyme.
Ramezani M; Shamsara J
Comb Chem High Throughput Screen; 2017; 20(8):719-725. PubMed ID: 28814230
[TBL] [Abstract][Full Text] [Related]
3. Identification of Non-Zinc Binding Inhibitors of MMP-2 Through Virtual Screening and Subsequent Rescoring.
Shamsara J
Drug Res (Stuttg); 2018 Sep; 68(9):529-535. PubMed ID: 29614516
[TBL] [Abstract][Full Text] [Related]
4. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
5. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.
Gao Q; Wang Y; Hou J; Yao Q; Zhang J
J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487
[TBL] [Abstract][Full Text] [Related]
6. Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking.
Wang Y; Yang L; Hou J; Zou Q; Gao Q; Yao W; Yao Q; Zhang J
J Biomol Struct Dyn; 2019 Feb; 37(3):649-670. PubMed ID: 29380672
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel selective MMP-9 inhibitors as potential anti-metastatic lead using structure-based hierarchical virtual screening and molecular dynamics simulation.
Kalva S; Agrawal N; Skelton AA; Saleena LM
Mol Biosyst; 2016 Jul; 12(8):2519-31. PubMed ID: 27250644
[TBL] [Abstract][Full Text] [Related]
8. Combined structure- and ligand-based pharmacophore modeling and molecular dynamics simulation studies to identify selective inhibitors of MMP-8.
Kalva S; Vinod D; Saleena LM
J Mol Model; 2014 May; 20(5):2191. PubMed ID: 24756550
[TBL] [Abstract][Full Text] [Related]
9. Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening.
Gimeno A; Cuffaro D; Nuti E; Ojeda-Montes MJ; Beltrán-Debón R; Mulero M; Rossello A; Pujadas G; Garcia-Vallvé S
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361703
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
[TBL] [Abstract][Full Text] [Related]
11. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
[TBL] [Abstract][Full Text] [Related]
12. Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors.
Laghezza A; Luisi G; Caradonna A; Di Pizio A; Piemontese L; Loiodice F; Agamennone M; Tortorella P
Bioorg Med Chem; 2020 Feb; 28(3):115257. PubMed ID: 31874775
[TBL] [Abstract][Full Text] [Related]
13. Virtual High-Throughput Screening for Matrix Metalloproteinase Inhibitors.
Choi JY; Fuerst R
Methods Mol Biol; 2017; 1579():259-271. PubMed ID: 28299742
[TBL] [Abstract][Full Text] [Related]
14. Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies.
Nuti E; Cuffaro D; Bernardini E; Camodeca C; Panelli L; Chaves S; Ciccone L; Tepshi L; Vera L; Orlandini E; Nencetti S; Stura EA; Santos MA; Dive V; Rossello A
J Med Chem; 2018 May; 61(10):4421-4435. PubMed ID: 29727184
[TBL] [Abstract][Full Text] [Related]
15. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
[TBL] [Abstract][Full Text] [Related]
16. Receptor-based 3D-QSAR approach to find selectivity features of flexible similar binding sites: case study on MMP-12/MMP-13.
Hadizadeh F; Shamsara J
Int J Bioinform Res Appl; 2015; 11(4):326-46. PubMed ID: 26561318
[TBL] [Abstract][Full Text] [Related]
17. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
[TBL] [Abstract][Full Text] [Related]
18. Identification of matrix metalloproteinase inhibitors by chemical arrays.
Kawatani M; Fukushima Y; Kondoh Y; Honda K; Sekine T; Yamaguchi Y; Taniguchi N; Osada H
Biosci Biotechnol Biochem; 2015; 79(10):1597-602. PubMed ID: 25988721
[TBL] [Abstract][Full Text] [Related]
19. Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.
Di Pizio A; Laghezza A; Tortorella P; Agamennone M
ChemMedChem; 2013 Sep; 8(9):1475-82, 1421. PubMed ID: 23873724
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of bicyclic molecular scaffolds (BTAa): an investigation towards new selective MMP-12 inhibitors.
Mannino C; Nievo M; Machetti F; Papakyriakou A; Calderone V; Fragai M; Guarna A
Bioorg Med Chem; 2006 Nov; 14(22):7392-403. PubMed ID: 16899369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
